// App-Quantinova.ai

316TiP : BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC)

Researchers

Presenter

  • T.Dalvi

Principal Investigators

  • K.A.Gelmon

  • R.Dent

  • M.Pegram

  • S.Loibl

  • Y.Tazir

  • A.Milner

  • J.Lewis

Medical Centers

  • Medical Evidence and Observational Research, AstraZeneca, Gaithersburg, MD, USA

  • Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

  • Division of Radiation Oncology, National Cancer Centre Singapore Duke-NUS Graduate Medical School, Singapore

  • Breast Cancer Oncology Program, Stanford Women's Cancer Center, Palo Alto, CA, USA

  • Medicine and Research, German Breast Group, Neu-Isenburg, Germany

  • Medical Evidence and Observational Research, AstraZeneca, Wedel, Germany

  • Biostatistics and Information Sciences, AstraZeneca, Cambridge, UK

  • Global Medicines Development, AstraZeneca, Cambridge, UK

Locations

  • United States

  • Canada

  • Singapore

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Alpha thalassemia mental retardation X-linked protein

  • BRCA1 associated RING domain 1

  • Checkpoint kinase 1

  • checkpoint kinase 2

  • Human epidermal growth factor receptor 2

  • BRCA mutation

  • Partner and localizer of BRCA2

  • RAD51 Paralog C

  • BRCA1 interacting protein

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Olaparib

  • ribose

Outcome

  • N/A

Study Design

  • Observational

  • Non Interventional

  • Prospective

  • Cross-Sectional

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved